SCHEMBL19593

SCHEMBL19593

Brc1ccc(N2CCOCC2)nc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 1/20 0.70
ALDH1A1 P00352 5/20 0.55
HPGD P15428 3/20 0.55
HSD17B10 Q99714 3/20 0.55
KDM4E B2RXH2 2/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
CYP1A2 P05177 1/20 0.55
CYP2C9 P11712 1/20 0.55
MEN1 O00255 1/20 0.55
LMNA P02545 1/20 0.55
GAA P10253 1/20 0.55
MAPT P10636 1/20 0.55
HTT P42858 1/20 0.55
RECQL P46063 1/20 0.55
KMT2A Q03164 1/20 0.55
TDP1 Q9NUW8 1/20 0.55
CNR2 P34972 6/20 0.53
GRIN2D O15399 1/20 0.51
GRIN3B O60391 1/20 0.51
GRIN1 Q05586 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14167598 0.93 AKR1C3 (0.63) AKR1C3ALDH1A1HPGDHSD17B10KDM4E
SCHEMBL5739833 0.93 AKR1C3 (0.63) AKR1C3ALDH1A1HPGDHSD17B10KDM4E
SCHEMBL5236585 0.86 AKR1C3 (0.61) AKR1C3ALDH1A1KDM4EMEN1LMNA
SCHEMBL2255519 0.82 GRIN2D (0.56) AKR1C3ALDH1A1SMN1; SMN2LMNAMAPT
SCHEMBL742515 0.82 GRIN2D (0.56) AKR1C3ALDH1A1SMN1; SMN2LMNAMAPT
SCHEMBL30020512 0.82 GRIN2D (0.56) AKR1C3ALDH1A1SMN1; SMN2LMNAMAPT
Hydrochloric Acid SCHEMBL6997406 0.81 GRIN2D (0.54) AKR1C3ALDH1A1SMN1; SMN2LMNAMAPT
SCHEMBL3573336 0.81 GRIN2D (0.54) AKR1C3ALDH1A1CYP1A2LMNAMAPT
SCHEMBL31196073 0.81 GRIN2D (0.54) AKR1C3ALDH1A1CYP1A2LMNAMAPT
SCHEMBL5238015 0.81 AKR1C3 (0.56) AKR1C3ALDH1A1KDM4ESMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 256 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3856736-B1 NOVEL COMPOUNDS AS NADPH OXIDASE INHIBITORS CALLIDITAS THERAPEUTICS SUISSE SA (CH) 2026-05-06 EP disclosed
EP-4709373-A2 HETEROCYCLIC COMPOUNDS FOR IMAGING AGGREGATED TAU IN TAUOPATHIES University of Pittsburgh - Of the Commonwealth System of Higher Education (US) 2026-03-18 EP disclosed
US-20250382277-A1 SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF UNIV ARIZONA (US) 2025-12-18 US disclosed
US-20250179012-A1 SYNTHESIS OF SULFUR(VI) COMPOUNDS AND REAGENTS FOR SAME H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. 2025-06-05 US disclosed
EP-4551570-A1 NOVEL COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF Dong-A ST Co., Ltd. (KR) 2025-05-14 EP disclosed
EP-4543887-A2 SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF Arizona Board of Regents on behalf of The University of Arizona (US) 2025-04-30 EP disclosed
US-12286455-B2 Anthelmintic depsipeptide compounds Boehringer Ingelheim Animal Health USA Inc. (US) 2025-04-29 US disclosed
US-12240836-B2 Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof DONG-A ST CO., LTD. (KR) 2025-03-04 US disclosed
CN-119403798-A Novel compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof 东亚ST 株式会社 2025-02-07 CN disclosed
US-12202816-B2 Compounds as NADPH oxidase inhibitors CALLIDITAS THERAPEUTICS SUISSE SA (CH) 2025-01-21 US disclosed
US-6689779-B2 PYRIDINE OR PYRIMIDINE SUBSTITUTED; ANTIBACTERIAL ACTIVITY; LOW TOXICITY DONG A PHARM. CO., LTD. (KR) 2004-02-10 US disclosed
EP-1347957-A1 DELTA 1-PYRROLINES USED AS PESTICIDES Bayer CropScience AG (DE) 2003-10-01 EP disclosed
US-20030166620-A1 Novel oxazolidinone derivatives and a process for the preparation thereof DONG A PHARM. CO., LTD. (KR) 2003-09-04 US disclosed
CN-1433413-A Oxazolidinone derivatives and process for their preparation DONG A PHARM CO LTD (KR) 2003-07-30 CN disclosed
CN-1419545-A 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors WYETH CORP (US) 2003-05-21 CN disclosed
US-6521618-B2 Antineoplastic agents, agents for treatment of osteoporosis and polycystic kidney disease WYETH 2003-02-18 US disclosed
WO-2002046151-A1 DELTA 1-PYRROLINES USED AS PESTICIDES BAYER CROPSCIENCE AG (DE) 2002-06-13 WO disclosed
US-20020013460-A1 Condensed pyridine compound EISAI CO., LTD 2002-01-31 US disclosed
US-6340759-B1 ANTISPASMODIC AGENTS EISAI CO., LTD. (JP) 2002-01-22 US disclosed
EP-1020445-A1 FUSED PYRIDINE DERIVATIVES Eisai Co., Ltd. (JP) 2000-07-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030166620-A1 Novel oxazolidinone derivatives and a process for the preparation thereof OXA1L, ODC1, PDCD4 AKR1C3 2366/4885ALDH1A1 939/4885HPGD 1495/4885
US-20020013460-A1 Condensed pyridine compound MUSK, HTR1A, PAX3 AKR1C3 3428/4885ALDH1A1 2989/4885HPGD 1216/4885
US-20250382277-A1 SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF CLK2, CLK3, CLK1 AKR1C3 3219/4885ALDH1A1 4568/4885HPGD 1612/4885
US-12240836-B2 Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof EIF2AK4, GCN1, GCGR AKR1C3 2033/4885ALDH1A1 3927/4885HPGD 841/4885
US-12202816-B2 Compounds as NADPH oxidase inhibitors CYBB, NOX1, NOX4 AKR1C3 351/4885ALDH1A1 285/4885HPGD 21/4885
US-20250179012-A1 SYNTHESIS OF SULFUR(VI) COMPOUNDS AND REAGENTS FOR SAME TST, CBS, SQOR AKR1C3 3277/4885ALDH1A1 2224/4885HPGD 3455/4885
US-12286455-B2 Anthelmintic depsipeptide compounds VIP, PREP, DNPEP AKR1C3 2840/4885ALDH1A1 3037/4885HPGD 2900/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.